Welcome!

News Feed Item

Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma Severities

For U.S. Media Only

RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Diego. Tiotropium is being studied to determine its efficacy and safety in treating asthma patients and is not currently approved for this indication.

The first results from the Phase 3 GraziaTinA-asthma® study (NCT01316380) were presented at the meeting, and showed that tiotropium delivered via the Respimat® inhaler improved lung function response, as measured by forced expiratory volume in one second (FEV1), in patients with mild asthma who remained symptomatic while receiving low-dose inhaled corticosteroid (ICS) treatment.

A pre-specified subset of data from the Phase 3 MezzoTinA-asthma® trials (NCT01172808/NCT01172821) presented at the meeting showed that, in patients with moderate asthma who remained symptomatic while receiving medium-dose ICS therapy, the addition of once-daily tiotropium reduced airflow obstruction independently of allergic status, as measured by the TH2 phenotype biomarkers.

Another subset of data presented at AAAAI found the addition of once-daily tiotropium in the Phase 3 PrimoTinA-asthma® trials (NCT00772538/NCT00776984) improved lung function responses independently of concomitant use of a leukotriene receptor antagonist (LTRA) in patients with severe asthma.

"Even with current treatment options, approximately 40 percent of patients with asthma remain symptomatic," said Pierluigi Paggiaro, MD, Professor of Respiratory Medicine, University of Pisa, and lead author on the GraziaTinA-asthma® presentation. "It is important to investigate the efficacy and safety of new treatment options across different severities."

GraziaTinA-Asthma® Data Presented at AAAAI

The GraziaTinA-asthma® trial is a Phase 3, randomized, double-blind, parallel-group trial designed to evaluate tiotropium delivered via the Respimat® inhaler as an add-on treatment in patients with persistent asthma who remain symptomatic while receiving at least low-dose maintenance ICS treatment (200-400 mcg budesonide equivalent). The primary endpoint was FEV1 peak(0-3h) response (change from baseline) at 12 weeks. The key secondary endpoint was trough FEV1. Additional secondary endpoints included FEV1 area under the curve (AUC(0-3h)), peak expiratory flow (PEF) responses (measured with the AM2+® device) and Asthma Control Questionnaire (ACQ-7) score. Of 464 treated patients, 155 received tiotropium 5 mcg, 154 received tiotropium 2.5 mcg, and 155 received placebo.

In the study, both tiotropium doses were statistically significant compared to placebo in FEV1 peak(0-3h) response and in trough FEV1 response at Week 12:


Peak FEV1(0-3h) Response

(adjusted mean difference)

Trough FEV1 Response

(adjusted mean difference)

5 mcg

128 mL (P = 0.0005)

122 mL (P = 0.001)

2.5 mcg

159 mL (P < 0.0001)

110 mL (P = 0.0028)

The FEV1 AUC(0-3h) response for patients receiving tiotropium was statistically significant versus placebo, as were the adjusted mean PEFAM and PEFPM responses versus placebo at Week 12:


FEV1 AUC(0-3h)

Response

Adjusted Mean

PEFAM

Adjusted Mean

PEFPM

5 mcg

125 mL

(P = 0.0003)

25.6 L/min

(P < 0.0001)

27.6 L/min

(P < 0.0001)

2.5 mcg

149 mL

(P < 0.0001)

26.3 L/min

(P < 0.0001)

22.4 L/min

(P < 0.0001)

In the study, adjusted mean ACQ­-7 score, measured following treatment at 12 weeks, was similar across all treatment arms:

  • Tiotropium 5 mcg: 1.391
  • Tiotropium 2.5 mcg: 1.438
  • Placebo: 1.377

The incidence of reported adverse events (AEs) was similar across treatment groups: tiotropium 5 mcg, 32.3 percent; tiotropium 2.5 mcg, 31.2 percent; placebo, 29.0 percent.

"We are encouraged by these findings in mild asthma, as they build on previously presented positive results for tiotropium in moderate and severe asthma severities," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The data from the UniTinA-asthma® clinical trial program presented at AAAAI add to our understanding of tiotropium's potential in asthma patients."

MezzoTinA-Asthma® Data Presented at AAAAI

Using the accepted serum IgE and eosinophil counts as biomarkers for TH2 inflammatory status, TH2-low and TH2-high subgroups were pre-defined in the MezzoTinA-asthma® trials at baseline as total serum IgE ≤ or >430 mcg/L, or blood eosinophils ≤ or >0.6×109/L. Of 2081 patients in the full analysis who received tiotropium or placebo, 1221/1961 were reported with IgE >430 mcg/L and 404/1969 with an eosinophil count of >0.6×109/L.

Both doses of tiotropium had a similar effect on peak and trough FEV1 versus placebo, independent of IgE and eosinophil count:


Adjusted Mean Peak FEV1(0-3h) Response


Subgroup

IgE ≤430 mcg/L

Subgroup

IgE >430 mcg/L

Subgroup

Eosinophils
≤0.6x109L

Subgroup

Eosinophils

>0.6x109L

5 mcg

168 mL

193 mL

170 mL

240 mL

2.5 mcg

197 mL

237 mL

236 mL

176 mL

Trough FEV1 also improved with both doses of tiotropium versus placebo, independently of IgE and eosinophil count:


Adjusted Mean Trough FEV1 Response


Subgroup

IgE ≤430 mcg/L

Subgroup

IgE >430 mcg/L

Subgroup

Eosinophils

≤0.6x109L

Subgroup

Eosinophils

>0.6x109L

5 mcg

139 mL

152 mL

137 mL

182 mL

2.5 mcg

167 mL

188 mL

185 mL

158 mL

In all subgroups, peak FEV1(0–3h) and trough FEV1 responses among patients who received tiotropium were within the same magnitude as responses in the active comparator salmeterol group.

The most frequently reported treatment-emergent AEs in both MezzoTinA-asthma® Phase 3 studies included asthma, PEF rate decrease and nasopharyngitis.

PrimoTinA-Asthma® Data Presented at AAAAI

Of the 912 patients in the PrimoTinA-asthma® trials randomized to receive either tiotropium (n=456) or placebo (n=456) for 48 weeks, 205 reported pre-screening LTRA use, 200 received LTRA at baseline, and 187 had efficacy data at Week 24. Use of LTRAs was permitted during run-in and treatment. Subgroups were defined by pre-screening LTRA use: "Yes"/"No". Mean percent predicted FEV1 at baseline was 55 percent in both groups.


Peak FEV1*

(adjusted mean difference

from placebo)

Trough FEV1**

(adjusted mean difference

from placebo)

LTRA "Yes"

103±51 mL (P = 0.0454)

96±48 mL (P = 0.0442)

LTRA "No"

111±28 mL (P < 0.0001)

91±25 mL (P = 0.0003)

*Peak FEV1 improvements independent of concomitant LTRA use [interaction P = 0.5747]

**Trough FEV1 improvements independent of concomitant LTRA use [interaction P = 0.4639]

The most frequently reported treatment-emergent AEs in both PrimoTinA-asthma® Phase 3 studies included asthma, PEF rate decrease and nasopharyngitis.

About the UniTinA-Asthma® Clinical Trial Program

The comprehensive Phase 3 trial program, UniTinA-asthma®, includes a number of clinical trials in adults, adolescents and pediatric patients across different asthma severities who remain symptomatic on current treatment with inhaled corticosteroid (ICS). The program includes over 4,000 patients in more than 150 sites globally. Results from the PrimoTinA-asthma® studies in severe asthma patients were presented at the 2012 European Respiratory Society (ERS) Annual Congress in Vienna, Austria, with additional sub-analyses presented at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, the 2013 American Thoracic Society (ATS) International Conference, the ERS Annual Congress 2013 and the American College of Chest Physicians (ACCP) Annual Meeting (CHEST 2013). Results from the MezzoTinA-asthma® studies in moderate asthma patients were presented at the ERS Annual Congress 2013.

About Asthma

Asthma is a chronic disease characterized by airway inflammation and bronchoconstriction. When a person with asthma comes into contact with an asthma trigger (e.g. infections, pollen, smoke), their airways can become inflamed, swollen and constricted and excess mucus is produced. These reactions can cause the airways to become narrower and irritated, making it difficult to breathe. People suffering from asthma experience recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Asthma attacks occur when symptoms become more intense or frequent.

As of December 2012, an estimated 300 million people worldwide suffer from asthma. Estimates have shown that the number of people with asthma could grow by an additional 100 million people worldwide by 2025.

By avoiding asthma triggers, one can help to reduce the severity of asthma. Although asthma cannot be cured, appropriate management can control the disease in many patients. Despite current treatment options, approximately 40 percent of patients with asthma remain symptomatic.

Leading Respiratory Forward

Through research, treatments and patient-centric support services, the Boehringer Ingelheim (BI) lung health portfolio is designed to help address the challenges people living with a lung disease face every day. Leveraging the company's cutting edge science and leadership in chronic obstructive pulmonary disease (COPD), BI is researching new treatment approaches where needs persist. It is the company's goal to make a difference in the lives of patients with COPD, asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.us.boehringer-ingelheim.com

SOURCE Boehringer Ingelheim

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Some people worry that OpenStack is more flash then substance; however, for many customers this could not be farther from the truth. No other technology equalizes the playing field between vendors while giving your internal teams better access than ever to infrastructure when they need it. In his session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will talk through some real-world OpenStack deployments and look into the ways this can benefit customers of all sizes....
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...